Celltrion Q3 operating profit tops W500 bil. mark for 1st time

Celltrion, a biotech company, has announced that its operating profit for the third quarter of 2026 is expected to exceed 500 billion won for the first time. This significant milestone is driven by strong sales in global markets. The company's forecasted sales and operating profit for the quarter are 1.5 trillion won and 510 billion won, respectively, representing year-on-year increases of 45.8 percent and 69.2 percent. This achievement highlights Celltrion's growing presence in the global market and is likely to have a positive impact on the company's stock value.

Why it matters

Celltrion's operating profit has surpassed expectations, which could lead to increased investor confidence and a rise in the company's stock price. The strong earnings report may also boost the biotech sector as a whole.

Market impact

Transmission channels

Likely winners & losers

Explore the intelligence

MeridStreet does not reproduce source articles. The summary and analysis above are generated by MeridStreet from public headlines and its own market model; the original reporting belongs to The Korea Times. For information only — not financial advice.